ADRA2A

(redirected from alpha-2A adrenergic receptor)

ADRA2A

A gene on chromosome 10q24-q26 that encodes alpha-2A-adrenergic receptor, a member of the G protein-coupled receptor superfamily, which plays a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the CNS, smooth muscle contraction and thermoregulation.
 
ADRA2A agonists
Oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine.
 
ADRA2A antagonists
Yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Mentioned in ?
References in periodicals archive ?
INTUNIV, a non-stimulant and selective alpha-2A adrenergic receptor agonist1 is currently approved as a treatment for child and adolescent patients (6 to 17 years old) in Japan.
Substitution of a mutant alpha-2A adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic- sparing responses in vivo.
Intuniv, a once-daily formulation of guanfacine, is said to be the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
INTUNIV is a selective alpha-2A adrenergic receptor agonist.
Dexmedetomedine enhances the action of local anesthetics by acting on peripheral alpha-2A adrenergic receptors and when used in spinal anesthesia it enhances local anesthetic action by virtue of its spinal alpha 2 receptors.